Mission Therapeutics has appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017. Colin joined the board of Mission Therapeutics as a non-executive Director in July 2015. Michael Moore, Mission's Founder Chairman, will continue on the board and transition to the role of Deputy Chairman.

Prior to joining Mission Therapeutics, Colin was Chief Executive Officer of OSI Pharmaceuticals. He joined the company as a research scientist in 1989 and led the transformation from a technology platform services company into a profitable fully integrated biopharmaceutical organisation, becoming CEO in 1998. He was pivotal in the registration and launch of OSI's targeted therapeutic product, Tarceva (erlotinib) and also directed the Company's financing, corporate development and acquisition strategies, completing several major acquisitions and divestitures and raising over $1.5 billion in capital.